COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks
Review
[키워드] Affect
Antibiotics
Antiviral
approach
approved active compounds
Bacteria
benefit
Care
cathepsin L
CCL20
CCL4
Clinical data
Combination
Compound
condition
COVID-19
COVID-19 pandemic
Cytokine release syndrome
Cytokine storm
disease
drug
drugs
early administration
effective
endothelial
Health
host cells
IL-1B
IL-6
immunomodulatory therapy
Inflammatory
lysosomal
lysosomal enzyme
lysosome
lysosomotropic compounds
lysosomotropism
MERS
New
pandemic
Patient
patients with SARS-CoV-2
Prevent
promote
Prophylaxis
provide
Remdesivir
SARS-CoV-2
SARS-COV-2 infection
Strategy
Stress
supported
systemic inflammation
therapeutic targets
therapy
Treatment
triggered
viral entry
viral host cell entry
viruses
[DOI] 10.3390/ijms21144953 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ijms21144953 PMC 바로가기 [Article Type] Review